Mylan Faces EpiPen Shortage as Slowing Sales Trip Up Its Results
- Weaker sales of allergy device weighed on drugmaker’s revenue
- Patients, pharmacists reported trouble tracking down EpiPen
Photographer: Daniel Acker/Bloomberg
This article is for subscribers only.
Mylan NV’s EpiPen has been hard to find in some areas because of production problems, U.S. regulators said, as the drugmaker reported that declining sales of the lifesaving allergy-shot device weighed on its results.
The Food and Drug Administration posted a notification on its website on Wednesday saying that while EpiPen remains available, there are “intermittent supply constraints” due to delays at Pfizer Inc.’s Meridian Medical Technologies, which manufactures the device for Mylan.